FDA label 3a7c03fe-ca67-489d-a42d-0efedd312f08
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 2a74e8a0-b2fd-4d7f-8bf8-72148b1d3ae7
- SPL ID
- 3a7c03fe-ca67-489d-a42d-0efedd312f08
- Version
- 3
- Effective date
- 2012-02-06
- Source export date
- 2026-11-13
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2df682709a18af7b632162dce4573ac151d74d432118e70b8675083d83b89813/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:51:01
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 3a7c03fe-ca67-489d-a42d-0efedd312f08 | id | |
| spl set id | 2a74e8a0-b2fd-4d7f-8bf8-72148b1d3ae7 | set_id |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks) largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. SEROQUEL XR is not approved for the treatment of patients with dementia-related psychosis [ see Warnings and Precautions (5.1)]. SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of SEROQUEL XR or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL XR is not approved for use in pediatric patients [ see Warnings and Precautions (5.2)]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Antipsychotic drugs are associated with an increased risk of death. (5.1) Quetiapine is not approved for elderly patients with Dementia-Related Psychosis. (5.1) WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants for major depressive disorder and other psychiatric disorders. (5.2)
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions table
<table frame="box" ID="i978d2fbd-ef7c-4432-8454-c400237c5237"> <colgroup align="center"> <col valign="top"/> <col valign="top"/> <col valign="top"/> <col valign="top"/> <col valign="top"/> </colgroup> <thead> <tr styleCode="Botrule"> <th>Laboratory Analyte</th> <th>Indication</th> <th>Treatment Arm</th> <th>N</th> <th>Patients n (%)</th> </tr> </thead> <tbody> <tr> <td rowspan="8"> <paragraph>Total Cholesterol ≥240 mg/dL</paragraph> </td> <td rowspan="2"> <paragraph>Schizophrenia<footnote ID="FN1258653220-1">6 weeks duration</footnote> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>718</paragraph> </td> <td> <paragraph>67 (9%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>232</paragraph> </td> <td> <paragraph>21 (9%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Depression<footnote ID="FN1258653333-1">8 weeks duration</footnote> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>85</paragraph> </td> <td> <paragraph>6 (7%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>106</paragraph> </td> <td> <paragraph>3 (3%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph/> <paragraph>Bipolar Mania<footnote ID="FN1258653357-1">3 weeks duration</footnote> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>128</paragraph> </td> <td> <paragraph>9 (7%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>134</paragraph> </td> <td> <paragraph>5 (4%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Major Depressive Disorder (Adjunct Therapy)<footnote ID="FN1260029451-1">6 weeks duration</footnote> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>420</paragraph> </td> <td> <paragraph>67 (16%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>213</paragraph> </td> <td> <paragraph>15 (7%)</paragraph> </td> </tr> <tr> <td rowspan="8"> <paragraph>Triglycerides ≥200 mg/dL</paragraph> </td> <td rowspan="2"> <paragraph>Schizophrenia<footnoteRef IDREF="FN1258653220-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>659</paragraph> </td> <td> <paragraph>118 (18%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>214</paragraph> </td> <td> <paragraph>11 (5%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Depression<footnoteRef IDREF="FN1258653333-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>84 </paragraph> </td> <td> <paragraph>7 (8%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>93</paragraph> </td> <td> <paragraph>7 (8%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Mania<footnoteRef IDREF="FN1258653357-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>102</paragraph> </td> <td> <paragraph>15 (15%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>125</paragraph> </td> <td> <paragraph>8 (6%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Major Depressive Disorder (Adjunct Therapy)<footnoteRef IDREF="FN1260029451-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>458</paragraph> </td> <td> <paragraph>75 (16%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>223</paragraph> </td> <td> <paragraph>18 (8%)</paragraph> </td> </tr> <tr> <td rowspan="8"> <paragraph>LDL-Cholesterol ≥ 160 mg/dL</paragraph> </td> <td rowspan="2"> <paragraph>Schizophrenia<footnoteRef IDREF="FN1258653220-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>691</paragraph> </td> <td> <paragraph>47 (7%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>227</paragraph> </td> <td> <paragraph>17 (8%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Depression<footnoteRef IDREF="FN1258653333-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>86</paragraph> </td> <td> <paragraph>3 (4%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>104</paragraph> </td> <td> <paragraph>2 (2%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Mania<footnoteRef IDREF="FN1258653357-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>125</paragraph> </td> <td> <paragraph>5 (4%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>135</paragraph> </td> <td> <paragraph>2 (2%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Major Depressive Disorder (Adjunct Therapy)<footnoteRef IDREF="FN1260029451-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>457</paragraph> </td> <td> <paragraph>51 (11%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>219</paragraph> </td> <td> <paragraph>21 (10%)</paragraph> </td> </tr> <tr> <td rowspan="8"> <paragraph>HDL-Cholesterol ≤ 40 mg/dL</paragraph> </td> <td rowspan="2"> <paragraph>Schizophrenia<footnoteRef IDREF="FN1258653220-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>600</paragraph> </td> <td> <paragraph>87 (15%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>195</paragraph> </td> <td> <paragraph>23 (12%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Depression<footnoteRef IDREF="FN1258653333-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>78</paragraph> </td> <td> <paragraph>7 (9%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>83</paragraph> </td> <td> <paragraph>6 (7%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Mania<footnoteRef IDREF="FN1258653357-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>100</paragraph> </td> <td> <paragraph>19 (19%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>115</paragraph> </td> <td> <paragraph>15 (13%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Major Depressive Disorder (Adjunct Therapy)<footnoteRef IDREF="FN1260029451-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>470</paragraph> </td> <td> <paragraph>34 (7%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>230</paragraph> </td> <td> <paragraph>19 (8%)</paragraph> </td> </tr> </tbody> </table>
warnings and cautions table
<table frame="box" ID="if20e5a14-7a66-4f0f-81f0-9a2cb8562bfa"> <colgroup align="center"> <col valign="top"/> <col valign="top"/> <col valign="top"/> <col valign="top"/> </colgroup> <thead> <tr styleCode="Botrule"> <th>Laboratory Analyte</th> <th>Treatment Arm </th> <th>N</th> <th>Patients n (%)</th> </tr> </thead> <tbody> <tr> <td rowspan="3"> <paragraph>Cholesterol ≥ 240 mg/dL</paragraph> </td> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>213</paragraph> </td> <td> <paragraph>15 (7%)</paragraph> </td> </tr> <tr> <td> <paragraph>SEROQUEL XR 150 mg</paragraph> </td> <td> <paragraph>223</paragraph> </td> <td> <paragraph>41 (18%)</paragraph> </td> </tr> <tr> <td> <paragraph>SEROQUEL XR 300 mg</paragraph> </td> <td> <paragraph>197</paragraph> </td> <td> <paragraph>26 (13%)</paragraph> </td> </tr> <tr> <td rowspan="3"> <paragraph>Triglycerides ≥ 200 mg/dL</paragraph> </td> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>223</paragraph> </td> <td> <paragraph>18 (8%)</paragraph> </td> </tr> <tr> <td> <paragraph>SEROQUEL XR 150 mg</paragraph> </td> <td> <paragraph>232</paragraph> </td> <td> <paragraph>36 (16%)</paragraph> </td> </tr> <tr> <td> <paragraph>SEROQUEL XR 300 mg</paragraph> </td> <td> <paragraph>226</paragraph> </td> <td> <paragraph>39 (17%)</paragraph> </td> </tr> <tr> <td rowspan="3"> <paragraph>LDL-Cholesterol ≥ 160 mg/dL</paragraph> </td> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>219</paragraph> </td> <td> <paragraph>21 (10%)</paragraph> </td> </tr> <tr> <td> <paragraph>SEROQUEL XR 150 mg</paragraph> </td> <td> <paragraph>242</paragraph> </td> <td> <paragraph>29 (12%)</paragraph> </td> </tr> <tr> <td> <paragraph>SEROQUEL XR 300 mg</paragraph> </td> <td> <paragraph>215</paragraph> </td> <td> <paragraph>22 (10%)</paragraph> </td> </tr> <tr> <td rowspan="3"> <paragraph>HDL-Cholesterol ≤ 40 mg/dL</paragraph> </td> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>230</paragraph> </td> <td> <paragraph>19 (8%)</paragraph> </td> </tr> <tr> <td> <paragraph>SEROQUEL XR 150 mg</paragraph> </td> <td> <paragraph>238</paragraph> </td> <td> <paragraph>14 (6%)</paragraph> </td> </tr> <tr> <td> <paragraph>SEROQUEL XR 300 mg</paragraph> </td> <td> <paragraph>232</paragraph> </td> <td> <paragraph>20 (9%)</paragraph> </td> </tr> </tbody> </table>
warnings and cautions table
<table frame="box" ID="ic452144e-5235-422a-8784-abb10b799fee"> <colgroup align="center"> <col valign="top"/> <col valign="top"/> <col valign="top"/> <col valign="top"/> <col valign="top"/> </colgroup> <thead> <tr styleCode="Botrule"> <th>Laboratory Analyte</th> <th>Indication</th> <th>Treatment Arm</th> <th>N</th> <th>Patients n (%)</th> </tr> </thead> <tbody> <tr> <td rowspan="4"> <paragraph> <content styleCode="bold">Total Cholesterol ≥ 200 mg/dL</content> </paragraph> </td> <td rowspan="2"> <paragraph>Schizophrenia<footnote ID="FN1258655920-1">13- 17 years, 6 weeks duration</footnote> </paragraph> </td> <td> <paragraph>SEROQUEL</paragraph> </td> <td> <paragraph>107</paragraph> </td> <td> <paragraph>13 (12%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>56</paragraph> </td> <td> <paragraph>1 (2%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Mania<footnote ID="FN1258655968-1">10-17 years, 3 weeks duration</footnote> </paragraph> </td> <td> <paragraph>SEROQUEL</paragraph> </td> <td> <paragraph>159</paragraph> </td> <td> <paragraph>16 (10%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>66</paragraph> </td> <td> <paragraph>2 (3%)</paragraph> </td> </tr> <tr> <td rowspan="4"> <paragraph> <content styleCode="bold">Triglycerides ≥150 mg/dL</content> </paragraph> </td> <td rowspan="2"> <paragraph>Schizophrenia<footnoteRef IDREF="FN1258655920-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL</paragraph> </td> <td> <paragraph>103</paragraph> </td> <td> <paragraph>17 (17%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>51</paragraph> </td> <td> <paragraph>4 (8%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Mania<footnoteRef IDREF="FN1258655968-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL</paragraph> </td> <td> <paragraph>149</paragraph> </td> <td> <paragraph>32 (22%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>60 </paragraph> </td> <td> <paragraph>8 (13%)</paragraph> </td> </tr> <tr> <td rowspan="4"> <paragraph> <content styleCode="bold">LDL-Cholesterol ≥ 130 mg/dL</content> </paragraph> </td> <td rowspan="2"> <paragraph>Schizophrenia<footnoteRef IDREF="FN1258655920-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL</paragraph> </td> <td> <paragraph>112</paragraph> </td> <td> <paragraph>4 (4%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>60</paragraph> </td> <td> <paragraph>1 (2%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Mania<footnoteRef IDREF="FN1258655968-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL</paragraph> </td> <td> <paragraph>169</paragraph> </td> <td> <paragraph>13 (8%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>74</paragraph> </td> <td> <paragraph>4 (5%)</paragraph> </td> </tr> <tr> <td rowspan="4"> <paragraph> <content styleCode="bold">HDL-Cholesterol ≤ 40 mg/dL</content> </paragraph> </td> <td rowspan="2"> <paragraph>Schizophrenia<footnoteRef IDREF="FN1258655920-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL</paragraph> </td> <td> <paragraph>104</paragraph> </td> <td> <paragraph>16 (15%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>54</paragraph> </td> <td> <paragraph>10 (19%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Mania<footnoteRef IDREF="FN1258655968-1"/> </paragraph> </td> <td> <paragraph>SEROQUEL</paragraph> </td> <td> <paragraph>154</paragraph> </td> <td> <paragraph>16 (10%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>61</paragraph> </td> <td> <paragraph>4 (7%)</paragraph> </td> </tr> </tbody> </table>
warnings and cautions table
<table frame="box" ID="ia67f109c-63f8-4f67-8ade-020f7a5c78ff"> <colgroup align="center"> <col valign="top"/> <col valign="top"/> <col valign="top"/> <col valign="top"/> <col valign="top"/> </colgroup> <thead> <tr styleCode="Botrule"> <th>Vital sign</th> <th>Indication</th> <th>Treatment Arm</th> <th>N</th> <th>Patients n (%)</th> </tr> </thead> <tbody> <tr> <td rowspan="8" valign="middle"> <paragraph> <content styleCode="bold">Weight Gain ≥ 7% of Body Weight</content> </paragraph> </td> <td rowspan="2"> <paragraph>Schizophrenia </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>907</paragraph> </td> <td> <paragraph>90 (10%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>299</paragraph> </td> <td> <paragraph>16 (5%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Mania </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>138</paragraph> </td> <td> <paragraph>7 (5%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>150</paragraph> </td> <td> <paragraph>0 (0%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Bipolar Depression </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>110</paragraph> </td> <td> <paragraph>9 (8%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>125</paragraph> </td> <td> <paragraph>1 (1%)</paragraph> </td> </tr> <tr> <td rowspan="2"> <paragraph>Major Depressive Disorder (Adjunctive Therapy) </paragraph> </td> <td> <paragraph>SEROQUEL XR</paragraph> </td> <td> <paragraph>616</paragraph> </td> <td> <paragraph>32 (5%)</paragraph> </td> </tr> <tr> <td> <paragraph>Placebo</paragraph> </td> <td> <paragraph>302</paragraph> </td> <td> <paragraph>5 (2%)</paragraph> </td> </tr> </tbody> </table>
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Most common adverse reactions (incidence ≥5% and twice placebo) in decreasing frequency are: somnolence, dry mouth, constipation, dizziness, increased appetite, dyspepsia, weight gain, fatigue, dysarthria, and nasal congestion. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. The information below is derived from a clinical trial database for SEROQUEL XR consisting of approximately 3400 patients exposed to SEROQUEL XR for the treatment of Schizophrenia, Bipolar Disorder, and Major Depressive Disorder in placebo-controlled trials. This experience corresponds to approximately 1020.1 patient-years. Adverse reactions were assessed by collecting adverse reactions, results of physical examinations, vital signs, body weights, laboratory analyses and ECG results. Adverse reactions during exposure were obtained by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a smaller number of standardized event categories. In the tables and tabulations that follow, standard MedDRA terminology has been used to classify reported adverse reactions. The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Adverse Reactions Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled Trials Schizophrenia: There was no difference in the incidence and type of adverse reactions associated with discontinuation (6.4% (61/951) for SEROQUEL XR vs. 7.5% (24/319) for placebo) in a pool of controlled Schizophrenia trials. There were no adverse reactions leading to discontinuation that occurred at an incidence of ≥ 2% for SEROQUEL XR in Schizophrenia trials. Bipolar Disorder: Mania: In a single clinical trial in patients with bipolar mania, 4.6% (7/151) of patients on SEROQUEL XR discontinued due to an adverse reaction compared to 8.1% (13/160) on placebo. There were no adverse reactions leading to discontinuation that occurred at an incidence of ≥ 2% for SEROQUEL XR in the Bipolar Mania trial. Depression: In a single clinical trial in patients with bipolar depression, 14% (19/137) of patients on SEROQUEL XR discontinued due to an adverse reaction compared to 4% (5/140) on placebo. Somnolence ∗ was the only adverse reaction leading to discontinuation that occurred at an incidence of ≥ 2% in SEROQUEL XR in the Bipolar Depression trial. ∗ The adverse reaction term “somnolence” includes both “somnolence” and “sedation.” MDD, Adjunctive Therapy: In adjunctive therapy clinical trials in patients with MDD, 12.1% (76/627) of patients on SEROQUEL XR discontinued due to adverse reaction compared to 1.9% (6/309) on placebo. Somnolence * was the only adverse reaction leading to discontinuation that occurred at an incidence of ≥ 2% in SEROQUEL XR in MDD trials. Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials: In short-term placebo-controlled studies for schizophrenia the most commonly observed adverse reactions associated with the use of SEROQUEL XR (incidence of 5% or greater) and observed at a rate on SEROQUEL XR at least twice that of placebo were somnolence (25%), dry mouth (12%), dizziness (10%), and dyspepsia (5%). Adverse Reactions Occurring at an Incidence of 1% or More Among SEROQUEL XR Treated Patients in Short-Term, Placebo-Controlled Trials Table 11 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy of schizophrenia (up to 6 weeks) in 1% or more in patients treated with SEROQUEL XR (doses ranging from 300 to 800 mg/day) where the incidence in patients treated with SEROQUEL XR was greater than the incidence in placebo-treated patients. Table 11: Treatment-Emergent Adverse Reaction Incidence in 6-Week Placebo-Controlled Clinical Trials for the Treatment of Schizophrenia Body System/Preferred Term Placebo SEROQUEL XR (n=319) (n=951) Cardiac Disorders Tachycardia 1% 3% Eye Disorders Vision blurred 1% 2% Gastrointestinal Disorders Dry Mouth 1% 12% Constipation 5% 6% Dyspepsia 2% 5% Toothache 0% 2% General Disorders and Administration Site Conditions Fatigue 2% 3% Irritability 0% 1% Pyrexia 0% 1% Investigations Heart Rate Increased 1% 4% Metabolism and Nutrition Disorders Increased Appetite 0% 2% Musculoskeletal and Connective Tissue Disorders Muscle Spasms 1% 2% Nervous System Disorders Somnolence 10% 25% Dizziness 4% 10% Tremor 1% 2% Akathisia 1% 2% Extrapyramidal Symptoms 5% 8% Psychiatric Disorders Anxiety 1% 2% Schizophrenia 1% 2% Restlessness 1% 2% Vascular Disorders Orthostatic Hypotension 5% 7% Hypotension 1% 3% In a 3-week, placebo-controlled study in bipolar mania the most commonly observed adverse reactions associated with the use of SEROQUEL XR (incidence of 5% or greater) and observed at a rate on SEROQUEL XR at least twice that of placebo were somnolence (50%), dry mouth (34%), dizziness (10%), constipation (10%), weight gain (7%), dysarthria (5%), and nasal congestion (5%). Table 12 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy of bipolar mania (up to 3 weeks) in 1% or more of patients treated with SEROQUEL XR (doses ranging from 400 to 800 mg/day) where the incidence in patients treated with SEROQUEL XR was greater than the incidence in placebo-treated patients. Table 12: Treatment-Emergent Adverse Reactions in a 3-Week Placebo-Controlled Clinical Trial for the Treatment of Bipolar Mania Body System/Preferred Term PLACEBO SEROQUEL XR (n=160) (n=151) Cardiac Disorders Tachycardia 1% 2% Eye Disorders Vision blurred 1% 2% Gastrointestinal Disorders Dry Mouth 7% 34% Constipation 3% 10% Dyspepsia 4% 7% Toothache 1% 3% General Disorders and Administration Site Conditions Fatigue 4% 7% Sluggishness 1% 2% Pain 0% 1% Investigations Weight Gain 1% 7% Heart Rate Increased 0% 3% Injury, Poisoning And Procedural Complications Contusion 0% 1% Metabolism And Nutrition Disorders Increased Appetite 2% 4% Nervous System Disorders Extrapyramidal Symptoms 4% 7% Somnolence 12% 50% Dizziness 4% 10% Dysarthria 0% 5% Lethargy 1% 2% Postural Dizziness 0% 1% Musculoskeletal And Connective Tissue Disorders Back Pain 2% 3% Arthralgia 0% 1% Psychiatric Disorders Abnormal Dreams 0% 3% Bipolar I Disorder 0% 1% Respiratory, Thoracic and Mediastinal Disorders Nasal Congestion 1% 5% Dry Throat 0% 1% Vascular Disorders Orthostatic Hypotension 0% 3% In the 8-week placebo-controlled bipolar depression study, the most commonly observed adverse reactions associated with the use of SEROQUEL XR (incidence of 5% or greater) and observed at a rate on SEROQUEL XR at least twice that of placebo were somnolence (52%), dry mouth (37%), increased appetite (12%), weight gain (7%), dyspepsia (7%), and fatigue (6%). Table 13: enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy of bipolar depression (up to 8 weeks) in 1% or more of patients treated with SEROQUEL XR 300 mg/day where the incidence in patients treated with SEROQUEL XR was greater than the incidence in placebo-treated patients. Table 13: Treatment-Emergent Adverse Reactions in an 8-Week Placebo-Controlled Clinical Trial for the Treatment of Bipolar Depression Body System/Preferred Term Placebo SEROQUEL XR (n=140) (n=137) Ear And Labyrinth Disorders Ear Pain 1% 2% Gastrointestinal Disorders Dry Mouth 7% 37% Constipation 6% 8% Dyspepsia 1% 7% Toothache 0% 3% Abdominal Distension 0% 1% General Disorders and Administration Site Conditions Fatigue 2% 6% Irritability 3% 4% Immune System Disorders Seasonal Allergy 1% 2% Infections And Infestations Viral Gastroenteritis 1% 4% Urinary Tract Infection 0% 2% Sinusitis 1% 2% Investigations Weight Gain 1% 7% Heart Rate Increased 0% 2% Metabolism and Nutrition Disorder Increased Appetite 6% 12% Decreased Appetite 1% 2% Musculoskeletal And Connective Tissue Disorders Arthralgia 1% 4% Back Pain 1% 3% Muscle Spasms 1% 3% Myalgia 1% 2% Neck Pain 0% 2% Nervous System Disorders Somnolence 13% 52% Extrapyramidal Symptoms 1% 4% Dizziness 11% 13% Paraesthesia 2% 3% Disturbance in Attention 1% 2% Dysarthria 0% 2% Akathisia 0% 2% Hypersomnia 0% 2% Mental Impairment 0% 2% Migraine 1% 2% Restless Legs Syndrome 1% 2% Sinus Headache 1% 2% Psychiatric Disorders Abnormal Dreams 0% 3% Anxiety 1% 2% Confusional State 0% 2% Disorientation 0% 2% Libido Decreased 1% 2% Renal And Urinary Disorders Pollakiuria 1% 2% Respiratory, Thoracic And Mediastinal Disorders Sinus Congestion 1% 2% Skin And Subcutaneous Tissue Disorders Hyperhidrosis 1% 2% Vascular Disorders Orthostatic Hypotension 1% 2% In the 6-week placebo-controlled fixed dose adjunctive therapy clinical trials, for MDD, the most commonly observed adverse reactions associated with the use of SEROQUEL XR (incidence of 5% or greater and observed at a rate on SEROQUEL XR and at least twice that of placebo) were somnolence (150 mg: 37%; 300 mg: 43%), dry mouth (150 mg: 27%; 300 mg: 40%), fatigue (150 mg: 14%; 300 mg: 11%), constipation (300 mg only: 11%) and weight increased (300 mg only: 5%). Table 14 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during short-term adjunctive therapy of MDD (up to 6 weeks) in 1% or more of patients treated with SEROQUEL XR (at doses of either 150 mg or 300 mg/day) where the incidence in patients treated with SEROQUEL XR was greater than the incidence in placebo-treated patients. Table 14: Treatment-Emergent Adverse Reaction Incidence in Placebo-Controlled Adjunctive Therapy Clinical Trials for the Treatment of MDD by Fixed Dose Body System/Preferred Term Placebo (n=309) SEROQUEL XR 150 mg (n=315) SEROQUEL XR 300 mg (n=312) Ear And Labyrinth Disorders Vertigo 1% 2% 2% Eye Disorders Vision Blurred 1% 2% 1% Gastrointestinal Disorders Dry Mouth 8% 27% 40% Constipation 4% 6% 11% Nausea 7% 7% 8% Dyspepsia 2% 2% 3% Abdominal Distension 0% 0% 1% Vomiting 1% 3% 1% General Disorders and Administration Site Conditions Fatigue 4% 14% 11% Irritability 3% 4% 2% Chills 0% 1% 1% Infections And Infestations Upper Respiratory Tract Infection 2% 3% 2% Influenza 0% 2% 1% Injury, Poisoning And Procedural Complications Fall 1% 2% 0% Investigations Weight Increased 0% 3% 5% Metabolism And Nutrition Disorders Increased Appetite 3% 3% 5% Musculoskeletal And Connective Tissue Disorders Back pain 1% 3% 3% Muscle Spasms 1% 2% 1% Nervous System Disorders Somnolence 9% 37% 43% Dizziness 7% 11% 12% Extrapyramidal Symptoms 4% 4% 6% Hypersomnia 0% 1% 2% Dysarthria 0% 1% 1% Dysgeusia 0% 1% 1% Lethargy 1% 2% 1% Akathisia 1% 2% 2% Psychiatric Disorders Abnormal Dreams 1% 2% 2% Anxiety 1% 2% 2% Restlessness 1% 1% 2% Libido Decreased 0% 0% 1% Depression 1% 2% 1% Adverse Reactions Occurring at an Incidence of 5% or More Among SEROQUEL XR Treated Patients in Long-Term, Placebo-Controlled Trials In a longer-term placebo-controlled trial, adult patients with schizophrenia who remained clinically stable on SEROQUEL XR during open-label treatment for at least 4 months were randomized to placebo (n=103) or to continue on their current SEROQUEL XR (n=94) for up to 12 months of observation for possible relapse, the adverse reactions reported were generally consistent with those reported in the short-term, placebo-controlled trials. Insomnia (8.5%) and headache (7.4%) were the only adverse events reported by 5% or more patients. Adverse Reactions that occurred in <5% of patients and were considered drug-related (incidence greater than placebo and consistent with known pharmacology of drug class) in order of decreasing frequency: heart rate increased, hypotension, weight increased, tremor, akathisia, increased appetite, blurred vision, postural dizziness, pyrexia, dysarthria, dystonia, drooling, syncope, tardive dyskinesia, dysphagia, leukopenia, and rash. Adverse Reactions in clinical trials with quetiapine and not listed elsewhere in the label: nightmares, peripheral edema, rhinitis, eosinophilia, hypersensitivity, elevations in gamma-GT levels, and elevations in serum creatine phosphokinase (not associated with NMS). Extrapyramidal Symptoms (EPS): Dystonia Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. Four methods were used to measure EPS: (1) Simpson-Angus total score (mean change from baseline) which evaluates Parkinsonism and akathisia, (2) Barnes Akathisia Rating Scale (BARS) Global Assessment Score, (3) incidence of spontaneous complaints of EPS (akathisia, akinesia, cogwheel rigidity, extrapyramidal syndrome, hypertonia, hypokinesia, neck rigidity, and tremor), and (4) use of anticholinergic medications to treat emergent EPS. Adults: In placebo-controlled clinical trials with quetiapine, utilizing doses up to 800 mg per day, the incidence of any adverse reactions potentially related to EPS ranged from 8% to 11% for quetiapine and 4% to 11% for placebo. In three-arm placebo-controlled clinical trials for the treatment of schizophrenia, utilizing doses between 300 mg and 800 mg of SEROQUEL XR, the incidence of any adverse reactions potentially related to EPS was 8% for SEROQUEL XR and 8% for SEROQUEL (without evidence of being dose related), and 5% in the placebo group. In these studies, the incidence of the individual adverse reactions (akathisia, extrapyramidal disorder, tremor, dyskinesia, dystonia, restlessness, and muscle rigidity) was generally low and did not exceed 3% for any treatment group. At the end of treatment, the mean change from baseline in SAS total score and BARS Global Assessment score was similar across the treatment groups. The use of concomitant anticholinergic medications was infrequent and similar across the treatment groups. The incidence of extrapyramidal symptoms was consistent with that seen with the profile of SEROQUEL in schizophrenia patients. Table 15: Adverse Experiences Associated with Extrapyramidal Symptoms in Placebo-controlled Clinical Trials for Schizophrenia Preferred term Placebo (N=319) SEROQUEL XR 300 mg/day (N=91) SEROQUEL XR 400 mg/day (N=227) SEROQUEL XR 600 mg/day (N=310) SEROQUEL XR 800 mg/day (N=323) All Doses (N=951) n % n % n % n % n % n % Dystonic event 0 0.0 3 3.3 0 0.0 4 1.3 1 0.3 8 0.8 Parkinsonism 4 1.3 1 1.1 3 1.3 11 3.6 7 2.2 22 2.3 Akathisia 4 1.3 0 0.0 3 1.3 7 2.3 7 2.2 17 1.8 Dyskinetic event 2 0.6 2 2.2 1 0.4 1 0.3 1 0.3 5 0.5 Other extrapyramidal event 7 2.2 3 3.3 4 1.8 7 2.3 12 3.7 26 2.7 In a placebo-controlled clinical trial for the treatment of bipolar mania, utilizing the dose range of 400-800 mg/day of SEROQUEL XR, the incidence of any adverse reactions potentially related to EPS was 6.6% for SEROQUEL XR and 3.8% in the placebo group. In this study, the incidence of the individual adverse reactions (akathisia, extrapyramidal disorder, tremor, dystonia, restlessness, and cogwheel rigidity) did not exceed 2.0% for any adverse reaction. Table 16: Adverse Experiences Associated with Extrapyramidal Symptoms in a Placebo-controlled Clinical Trial for Bipolar Mania Preferred term Placebo (N=160) SEROQUEL XR (N=151) n % n % Dystonic event 0 0.0 1 0.7 Parkinsonism 3 1.9 4 2.7 Akathisia 1 0.6 2 1.3 Other extrapyramidal event 2 1.3 3 2.0 In a placebo-controlled clinical trial for the treatment of bipolar depression utilizing 300 mg of SEROQUEL XR, the incidence of any adverse reactions potentially related to EPS was 4.4% for SEROQUEL XR and 0.7% in the placebo group. In this study, the incidence of the individual adverse reactions (akathisia, extrapyramidal disorder, tremor, dystonia, hypertonia) did not exceed 1.5% for any individual adverse reaction. Table 17: Adverse Experiences Associated with Extrapyramidal Symptoms in a Placebo-controlled Clinical Trial for Bipolar Depression Preferred term Placebo (N=140) SEROQUEL XR (N=137) n % n % Dystonic event 0 0.0 2 1.5 Parkinsonism 1 0.7 1 0.7 Akathisia 0 0.0 2 1.5 Other extrapyramidal event 0 0.0 1 0.7 In two placebo-controlled short-term adjunctive therapy clinical trials for the treatment of MDD utilizing between 150 mg and 300 mg of SEROQUEL XR, the incidence of any adverse reactions potentially related to EPS was 5.1% for SEROQUEL XR and 4.2% for the placebo group. Table 18 shows the percentage of patients experiencing adverse reactions potentially associated with EPS in adjunct clinical trials for MDD by dose: Table 18: Adverse Reactions Potentially Associated with EPS in MDD Trials by Dose, Adjunctive Therapy Clinical Trials (6 weeks duration) Preferred term Placebo (N=309) SEROQUEL XR 150 mg/day (N=315) SEROQUEL XR 300 mg/day (N=312) All Doses (N=627) n % n % n % n % Dystonic event 0 0.0 1 0.3 0 0.0 1 0.2 Parkinsonism 5 1.6 3 1.0 4 1.3 7 1.1 Akathisia 3 1.0 5 1.6 8 2.6 13 2.1 Dyskinetic event 0 0.0 0 0.0 1 0.3 1 0.2 Other extrapyramidal event 5 1.6 5 1.6 7 2.2 12 1.9 Children and Adolescents: Safety and effectiveness of SEROQUEL XR have not been established in pediatric patients and SEROQUEL XR is not approved for patients under the age of 18 years. In a short-term placebo-controlled monotherapy trial in adolescent patients with schizophrenia (6-week duration), the aggregated incidence of extrapyramidal symptoms was 12.9% for SEROQUEL and 5.3% for placebo, though the incidence of the individual adverse events (eg, akathisia, tremor, extrapyramidal disorder, hypokinesia, restlessness, psychomotor hyperactivity, muscle rigidity, dyskinesia) did not exceed 4.1% in any treatment group. In a short-term placebo-controlled monotherapy trial in children and adolescent patients with bipolar mania (3-week duration), the aggregated incidence of extrapyramidal symptoms was 3.6% for SEROQUEL and 1.1% for placebo. Table 19 below presents a listing of patients with adverse experiences potentially associated with EPS in the short-term placebo-controlled monotherapy trial in adolescent patients with schizophrenia (6-week duration). Table 19 Adverse experiences potentially associated with EPS in the short-term placebo-controlled monotherapy trial in adolescent patients with schizophrenia (6-week duration). Preferred term Placebo (N=75) SEROQUEL 400 mg/day (N=73) SEROQUEL 800 mg/day (N=74) All SEROQUEL (N=147) n : % n % n % n % Dystonic event 0 0.0 2 2.7 0 0.0 2 1.4 Parkinsonism 2 2.7 4 5.5 4 5.4 8 5.4 Akathisia 3 4.0 3 4.1 4 5.4 7 4.8 Dyskinetic event 0 0.0 2 2.7 0 0.0 2 1.4 Other extrapyramidal event 0 0.0 2 2.7 2 2.7 4 2.7 Table 20 below presents a listing of patients with Adverse Experiences potentially associated with EPS in a short-term placebo-controlled monotherapy trial in children and adolescent patients with bipolar mania (3-week duration) Table 20: Adverse experiences potentially associated with EPS in a short-term placebo-controlled monotherapy trial in children and adolescent patients with bipolar mania (3-week duration) Preferred term Placebo (N=90) SEROQUEL 400 mg/day (N=95) SEROQUEL 600 mg/day (N=98) All SEROQUEL (N=193) n % n % n % n % Parkinsonism 1 1.1 2 2.1 1 1.0 3 1.6 Akathisia 0 0.0 1 1.0 1 1.0 2 1.0 Other extrapyramidal event 0 0.0 1 1.1 1 1.0 2 1.0 Children and Adolescents: Safety and effectiveness of SEROQUEL XR have not been established in pediatric patients and SEROQUEL XR is not approved for patients under the age of 18 years. In acute placebo-controlled trials in children and adolescent patients with schizophrenia (6-week duration) or bipolar mania (3-week duration), the incidence of increased appetite was 7.6% for SEROQUEL compared to 2.4% for placebo. In a 26-week open-label study that enrolled patients from the above two pediatric trials, the incidence of increased appetite was 7% for SEROQUEL. 6.2 Vital Signs and Laboratory Values Hyperglycemia, hyperlipidemia, weight gain, orthostatic hypotension and changes in thyroid hormone levels have been reported with quetiapine. Increases in blood pressure have also been reported with quetiapine in children and adolescents [ see Warnings and Precautions (5.4, 5.5, 5.6, 5.8, 5.9 and 5.14)]. Laboratory Changes: Neutrophil Counts In three-arm SEROQUEL XR placebo-controlled monotherapy clinical trials, among patients with a baseline neutrophil count ≥ 1.5 x 10 9 /L, the incidence of at least one occurrence of neutrophil count <1.5 x 10 9 /L was 1.5% in patients treated with SEROQUEL XR and 1.5% for SEROQUEL, compared to 0.8% in placebo-treated patients. In placebo-controlled monotherapy clinical trials involving 3368 patients on quetiapine fumarate and 1515 on placebo, the incidence of at least one occurrence of neutrophil count <1.0 x 10 9 /L among patients with a normal baseline neutrophil count and at least one available follow up laboratory measurement was 0.3% (10/2967) in patients treated with quetiapine, compared to 0.1% (2/1349) in patients treated with placebo. Patients with a pre-existing low WBC or a history of drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue SEROQUEL XR at the first sign of a decline in WBC in absence of other causative factors [ see Warnings and Precautions (5.10)]. Decreased Hemoglobin In short-term placebo-controlled trials, decreases in hemoglobin to ≤ 13 g/dL males, ≤ 12 g/dL females on at least one occasion occurred in 8.3% (594/7155) of quetiapine-treated patients compared to 6.2% (219/3536) of patients treated with placebo. In a database of controlled and uncontrolled clinical trials, decreases in hemoglobin to ≤ 13 g/dL males, ≤ 12 g/dL females on at least one occasion occurred in 11% (2277/20729) of quetiapine-treated patients. ECG Changes: 2.5% of SEROQUEL XR patients, and 2.3% of placebo patients, had tachycardia (>120 bpm) at any time during the trials. SEROQUEL XR was associated with a mean increase in heart rate, assessed by ECG, of 6.3 beats per minute compared to a mean increase of 0.4 beats per minute for placebo. This is consistent with the rates for SEROQUEL. The incidence of adverse reactions of tachycardia was 1.9% for SEROQUEL XR compared to 0.5% for placebo. SEROQUEL use was associated with a mean increase in heart rate, assessed by ECG, of 7 beats per minute compared to a mean increase of 1 beat per minute among placebo patients. The slight tendency for tachycardia may be related to quetiapine’s potential for inducing orthostatic changes [ see Warnings and Precautions (5.8)]. Children and Adolescents: Safety and effectiveness of SEROQUEL XR have not been established in pediatric patients. In the acute (6-week) schizophrenia trial in adolescents, potentially clinically significant increases in heart rate (> 110 bpm) occurred in 5.2% of patients receiving SEROQUEL 400 mg and 8.5% of patients receiving SEROQUEL 800 mg compared to 0% of patients receiving placebo. Mean increases in heart rate were 3.8 bpm and 11.2 bpm for SEROQUEL 400 mg and 800 mg groups, respectively, compared to a decrease of 3.3 bpm in the placebo group [ see Warnings and Precautions (5.8)]. In the acute (3-week) bipolar mania trial in children and adolescents, potentially clinically significant increases in heart rate (> 110 bpm) occurred in 1.1% of patients receiving SEROQUEL 400 mg and 2.4% of patients receiving SEROQUEL 600 mg compared to 0% of patients receiving placebo. Mean increases in heart rate were 12.8 bpm and 13.4 bpm for SEROQUEL 400 mg and 600 mg groups, respectively, compared to a decrease of 1.7 bpm in the placebo group [ see Warnings and Precautions (5.8)]. 6.3 Post Marketing Experience The following adverse reactions were identified during post approval use of SEROQUEL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions reported since market introduction which were temporally related to SEROQUEL therapy include anaphylactic reaction and galactorrhea. Other adverse reactions reported since market introduction, which were temporally related to SEROQUEL therapy, but not necessarily causally related, include the following: agranulocytosis, cardiomyopathy, hyponatremia, myocarditis, rhabdomyolysis, syndrome of inappropriate antidiuretic hormone secretion (SIADH), Stevens-Johnson syndrome (SJS), and decreased platelets. In post-marketing clinical trials, elevations in total cholesterol (predominantly LDL cholesterol), dyspnea, palpitations, somnambulism (and other related events) and hypothermia have been reported.
adverse reactions table
<table frame="void" rules="groups" ID="i193d482b-e239-4e64-8278-ed42fb1b7eeb"> <caption>Table 11: Treatment-Emergent Adverse Reaction Incidence in 6-Week Placebo-Controlled Clinical Trials for the Treatment of Schizophrenia </caption> <colgroup> <col align="left" valign="top"/> <col align="left" valign="top"/> <col align="left" valign="top"/> </colgroup> <thead> <tr> <th/> <th/> <th/> </tr> <tr> <th>Body System/Preferred Term</th> <th>Placebo</th> <th>SEROQUEL XR</th> </tr> <tr styleCode="Botrule"> <th/> <th>(n=319)</th> <th>(n=951)</th> </tr> </thead> <tbody> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Cardiac Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Tachycardia</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Eye Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Vision blurred</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Gastrointestinal Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Dry Mouth</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>12%</paragraph> </td> </tr> <tr> <td> <paragraph>Constipation</paragraph> </td> <td> <paragraph>5%</paragraph> </td> <td> <paragraph>6%</paragraph> </td> </tr> <tr> <td> <paragraph>Dyspepsia</paragraph> </td> <td> <paragraph>2%</paragraph> </td> <td> <paragraph>5%</paragraph> </td> </tr> <tr> <td> <paragraph>Toothache</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">General Disorders and Administration Site Conditions</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Fatigue</paragraph> </td> <td> <paragraph>2%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td> <paragraph>Irritability</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>1%</paragraph> </td> </tr> <tr> <td> <paragraph>Pyrexia</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Investigations</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Heart Rate Increased</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>4%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Metabolism and Nutrition Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Increased Appetite</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Muscle Spasms</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Nervous System Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Somnolence </paragraph> </td> <td> <paragraph>10%</paragraph> </td> <td> <paragraph>25%</paragraph> </td> </tr> <tr> <td> <paragraph>Dizziness</paragraph> </td> <td> <paragraph>4%</paragraph> </td> <td> <paragraph>10%</paragraph> </td> </tr> <tr> <td> <paragraph>Tremor</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Akathisia</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Extrapyramidal Symptoms </paragraph> </td> <td> <paragraph>5%</paragraph> </td> <td> <paragraph>8%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Psychiatric Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Anxiety</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Schizophrenia</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Restlessness</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Vascular Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Orthostatic Hypotension</paragraph> </td> <td> <paragraph>5%</paragraph> </td> <td> <paragraph>7%</paragraph> </td> </tr> <tr> <td> <paragraph>Hypotension</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table frame="hsides" rules="groups" ID="i039fba33-5e0e-44c9-8083-6e66fe43641e"> <caption>Table 12: Treatment-Emergent Adverse Reactions in a 3-Week Placebo-Controlled Clinical Trial for the Treatment of Bipolar Mania </caption> <colgroup> <col align="left" valign="top"/> <col align="left" valign="top"/> <col align="left" valign="top"/> </colgroup> <thead> <tr> <th/> <th/> <th/> </tr> <tr> <th>Body System/Preferred Term</th> <th>PLACEBO</th> <th>SEROQUEL XR</th> </tr> <tr styleCode="Botrule"> <th/> <th>(n=160)</th> <th>(n=151)</th> </tr> </thead> <tbody> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Cardiac Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Tachycardia</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Eye Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Vision blurred</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Gastrointestinal Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Dry Mouth</paragraph> </td> <td> <paragraph>7%</paragraph> </td> <td> <paragraph>34%</paragraph> </td> </tr> <tr> <td> <paragraph>Constipation</paragraph> </td> <td> <paragraph>3%</paragraph> </td> <td> <paragraph>10%</paragraph> </td> </tr> <tr> <td> <paragraph>Dyspepsia</paragraph> </td> <td> <paragraph>4%</paragraph> </td> <td> <paragraph>7%</paragraph> </td> </tr> <tr> <td> <paragraph>Toothache</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">General Disorders and Administration Site Conditions</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Fatigue</paragraph> </td> <td> <paragraph>4%</paragraph> </td> <td> <paragraph>7%</paragraph> </td> </tr> <tr> <td> <paragraph>Sluggishness</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Pain</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Investigations</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Weight Gain</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>7%</paragraph> </td> </tr> <tr> <td> <paragraph>Heart Rate Increased</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Injury, Poisoning And Procedural Complications</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Contusion</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Metabolism And Nutrition Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Increased Appetite</paragraph> </td> <td> <paragraph>2%</paragraph> </td> <td> <paragraph>4%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Nervous System Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Extrapyramidal Symptoms </paragraph> </td> <td> <paragraph>4%</paragraph> </td> <td> <paragraph>7%</paragraph> </td> </tr> <tr> <td> <paragraph>Somnolence </paragraph> </td> <td> <paragraph>12%</paragraph> </td> <td> <paragraph>50%</paragraph> </td> </tr> <tr> <td> <paragraph>Dizziness</paragraph> </td> <td> <paragraph>4%</paragraph> </td> <td> <paragraph>10%</paragraph> </td> </tr> <tr> <td> <paragraph>Dysarthria</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>5%</paragraph> </td> </tr> <tr> <td> <paragraph>Lethargy</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Postural Dizziness</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Musculoskeletal And Connective Tissue Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Back Pain</paragraph> </td> <td> <paragraph>2%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td> <paragraph>Arthralgia</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Psychiatric Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Abnormal Dreams</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td> <paragraph>Bipolar I Disorder</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Nasal Congestion</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>5%</paragraph> </td> </tr> <tr> <td> <paragraph>Dry Throat</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Vascular Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Orthostatic Hypotension</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table frame="void" rules="groups" ID="i80423872-3c42-4e2e-8efc-f142db91b9c8"> <caption>Table 13: Treatment-Emergent Adverse Reactions in an 8-Week Placebo-Controlled Clinical Trial for the Treatment of Bipolar Depression </caption> <colgroup> <col align="left" valign="top"/> <col align="left" valign="top"/> <col align="left" span="1" valign="top"/> </colgroup> <thead> <tr> <th/> <th/> <th/> </tr> <tr> <th>Body System/Preferred Term</th> <th>Placebo</th> <th>SEROQUEL XR</th> </tr> <tr styleCode="Botrule"> <th/> <th>(n=140)</th> <th>(n=137)</th> </tr> </thead> <tbody> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Ear And Labyrinth Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Ear Pain</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Gastrointestinal Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Dry Mouth</paragraph> </td> <td> <paragraph>7%</paragraph> </td> <td> <paragraph>37%</paragraph> </td> </tr> <tr> <td> <paragraph>Constipation</paragraph> </td> <td> <paragraph>6%</paragraph> </td> <td> <paragraph>8%</paragraph> </td> </tr> <tr> <td> <paragraph>Dyspepsia</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>7%</paragraph> </td> </tr> <tr> <td> <paragraph>Toothache</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td> <paragraph>Abdominal Distension</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">General Disorders and Administration Site Conditions</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Fatigue</paragraph> </td> <td> <paragraph>2%</paragraph> </td> <td> <paragraph>6%</paragraph> </td> </tr> <tr> <td> <paragraph>Irritability</paragraph> </td> <td> <paragraph>3%</paragraph> </td> <td> <paragraph>4%</paragraph> </td> </tr> <tr> <td> <paragraph> <content styleCode="bold">Immune System Disorders</content> </paragraph> </td> <td/> <td/> </tr> <tr> <td> <paragraph>Seasonal Allergy</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Infections And Infestations</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Viral Gastroenteritis</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>4%</paragraph> </td> </tr> <tr> <td> <paragraph>Urinary Tract Infection</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Sinusitis</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Investigations</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Weight Gain</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>7%</paragraph> </td> </tr> <tr> <td> <paragraph>Heart Rate Increased</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Metabolism and Nutrition Disorder</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Increased Appetite</paragraph> </td> <td> <paragraph>6%</paragraph> </td> <td> <paragraph>12%</paragraph> </td> </tr> <tr> <td> <paragraph>Decreased Appetite</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Musculoskeletal And Connective Tissue Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Arthralgia</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>4%</paragraph> </td> </tr> <tr> <td> <paragraph>Back Pain</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td> <paragraph>Muscle Spasms</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td> <paragraph>Myalgia</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Neck Pain</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Nervous System Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Somnolence </paragraph> </td> <td> <paragraph>13%</paragraph> </td> <td> <paragraph>52%</paragraph> </td> </tr> <tr> <td> <paragraph>Extrapyramidal Symptoms </paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>4%</paragraph> </td> </tr> <tr> <td> <paragraph>Dizziness</paragraph> </td> <td> <paragraph>11%</paragraph> </td> <td> <paragraph>13%</paragraph> </td> </tr> <tr> <td> <paragraph>Paraesthesia</paragraph> </td> <td> <paragraph>2%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td> <paragraph>Disturbance in Attention</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Dysarthria</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Akathisia</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Hypersomnia</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Mental Impairment</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Migraine</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Restless Legs Syndrome</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Sinus Headache</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Psychiatric Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Abnormal Dreams</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>3%</paragraph> </td> </tr> <tr> <td> <paragraph>Anxiety</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Confusional State</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Disorientation</paragraph> </td> <td> <paragraph>0%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td> <paragraph>Libido Decreased</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Renal And Urinary Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Pollakiuria</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Respiratory, Thoracic And Mediastinal Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Sinus Congestion</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Skin And Subcutaneous Tissue Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Hyperhidrosis</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="3"> <paragraph> <content styleCode="bold">Vascular Disorders</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Orthostatic Hypotension</paragraph> </td> <td> <paragraph>1%</paragraph> </td> <td> <paragraph>2%</paragraph> </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.